Jeremy Sugarman, MD, MPH, MA is the Harvey M. Meyerhoff Professor of Bioethics and Medicine, professor of medicine, professor of Health Policy and Management, and deputy director for medicine of the Johns Hopkins Berman Institute of Bioethics. He is an internationally recognized leader in the field of biomedical ethics with particular expertise in the application of empirical methods and evidence-based standards for the evaluation and analysis of bioethical issues. His contributions to both medical ethics and policy include his work on the ethics of informed consent, umbilical cord blood banking, stem cell research, international HIV prevention research, global health and research oversight.
Dr. Sugarman is the author of over 250 articles, reviews and book chapters. He has also edited or co-edited four books (Beyond Consent: Seeking Justice in Research; Ethics of Research with Human Subjects: Selected Policies and Resources; Ethics in Primary Care; and Methods in Medical Ethics). Dr. Sugarman is an associate editor of Clinical Trials, a contributing editor for IRB, and is on the editorial boards of several academic journals.
Dr. Sugarman consults and speaks internationally on a range of issues related to bioethics. He has served as senior policy and research analyst for the White House Advisory Committee on Human Radiation Experiments, consultant to the National Bioethics Advisory Commission, and Senior Advisor to the Presidential Commission for the Study of Bioethical Issues. He also served on the Maryland Stem Cell Research Commission.
He was the founding director of the Trent Center for Bioethics, Humanities and History of Medicine at Duke University where he was also a professor of medicine and philosophy. He is a faculty affiliate of the Kennedy Institute of Ethics at Georgetown University and an Academic Icon of the University of Malaya.
Dr. Sugarman currently serves on the Scientific and Research Advisory Board for the Canadian Blood Service, the Ethics and Public Policy Committee of the International Society for Stem Cell Research, and the Board of Directors of PRIM&R (Public Responsibility in Medicine and Research). He is co-chair of the Johns Hopkins’ Institutional Stem Cell Research Oversight Committee. In addition, he is chair of the Ethics Working Group of the HIV Prevention Trials Network and is the ethics officer for the Resuscitation Outcomes Consortium.
Dr. Sugarman has been elected as a member of the American Society of Clinical Investigation, Association of American Physicians, and the Institute of Medicine. He is a fellow of the American Association for the Advancement of Science, the American College of Physicians and the Hastings Center.
BS, Duke University
MD, Duke University
MPH, Johns Hopkins School of Hygiene and Public Health
MA, Georgetown University
- Sugarman J. Bioethical challenges with HIV treatment as prevention. CID 2014; 59: S32-S34. PMID: 24926031.
- Sugarman J, Califf RM. “Ethics and Regulatory Complexities for Pragmatic Clinical Trials,” Journal of the American Medical Association 311: 2381-2382; June 2014.
- Dasgupta I, Bollinger J, Mathews DJH, Neumann N, Rattani A, Sugarman J. “Patients’ Attitudes Toward the Donation of Biological Materials for the Derivation of Induced Pluripotent Stem Cells,” Cell Stem Cell 14: 9-12; January 2014; PMID: 24388172.
- Sugarman J, Rose S, Metzger D. “Ethical issues in HIV prevention research with people who inject drugs,” Clinical Trials 11: 239-45; April 2014; PMID: 24127238.
- Crump JA, Sugarman J, and the Working Group on Ethics Guidelines for Global Health Training (WEIGHT). “Ethics and Best Practice Guidelines for Training Experiences in Global Health,” American Journal of Tropical Medicine and Hygiene 83: 1178-1182; 2010; PMID: 21118918.
- Weinfurt K, Hall M, King NMP, Friedman J, Schulman K, Sugarman J. “Disclosure of financial relationships to clinical research participants: goals, evidence, and recommendations,” New England Journal of Medicine 361: 916-21; August 2009; PMID: 19710491.
- Lavori P, Wilt T, Sugarman J. “Quality assurance questionnaire for professionals fails to improve the quality of informed consent,” Clinical Trials 4: 638-649; November 2007; PMID: 18042573.